1
|
Xu J, Li Y, Li X, Li C, Shao T, Bai J, Chen H, Li X. Dissection of the potential characteristic of miRNA–miRNA functional synergistic regulations. ACTA ACUST UNITED AC 2013; 9:217-24. [DOI: 10.1039/c2mb25360g] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
2
|
Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IHG, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 2012; 7:e48086. [PMID: 23133552 PMCID: PMC3485010 DOI: 10.1371/journal.pone.0048086] [Citation(s) in RCA: 235] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Accepted: 09/20/2012] [Indexed: 12/19/2022] Open
Abstract
Background Osteosarcomas are the most common primary malignant tumors of bone and show multiple and complex genomic aberrations. miRNAs are non-coding RNAs capable of regulating gene expression at the post transcriptional level, and miRNAs and their target genes may represent novel therapeutic targets or biomarkers for osteosarcoma. In order to investigate the involvement of miRNAs in osteosarcoma development, global microarray analyses of a panel of 19 human osteosarcoma cell lines was performed. Principal findings We identified 177 miRNAs that were differentially expressed in osteosarcoma cell lines relative to normal bone. Among these, miR-126/miR-126*, miR-142-3p, miR-150, miR-223, miR-486-5p and members of the miR-1/miR-133a, miR-144/miR-451, miR-195/miR-497 and miR-206/miR-133b clusters were found to be downregulated in osteosarcoma cell lines. All miRNAs in the paralogous clusters miR-17-92, miR-106b-25 and miR-106a-92 were overexpressed. Furthermore, the upregulated miRNAs included miR-9/miR-9*, miR-21*, miR-31/miR-31*, miR-196a/miR-196b, miR-374a and members of the miR-29 and miR-130/301 families. The most interesting inversely correlated miRNA/mRNA pairs in osteosarcoma cell lines included miR-9/TGFBR2 and miR-29/p85α regulatory subunit of PI3K. PTEN mRNA correlated inversely with miR-92a and members of the miR-17 and miR-130/301 families. Expression profiles of selected miRNAs were confirmed in clinical samples. A set of miRNAs, miR-1, miR-18a, miR-18b, miR-19b, miR-31, miR-126, miR-142-3p, miR-133b, miR-144, miR-195, miR-223, miR-451 and miR-497 was identified with an intermediate expression level in osteosarcoma clinical samples compared to osteoblasts and bone, which may reflect the differentiation level of osteosarcoma relative to the undifferentiated osteoblast and fully differentiated normal bone. Significance: This study provides an integrated analysis of miRNA and mRNA in osteosarcoma, and gives new insight into the complex genetic mechanisms of osteosarcoma development and progression.
Collapse
Affiliation(s)
- Heidi M. Namløs
- The EuroBoNet Network of Excellence on Bone Tumours
- Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - Leonardo A. Meza-Zepeda
- The EuroBoNet Network of Excellence on Bone Tumours
- Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
- Norwegian Microarray Consortium, Department of Molecular Biosciences, University of Oslo, Oslo, Norway
| | - Tale Barøy
- The EuroBoNet Network of Excellence on Bone Tumours
- Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - Ingrid H. G. Østensen
- The EuroBoNet Network of Excellence on Bone Tumours
- Norwegian Microarray Consortium, Department of Molecular Biosciences, University of Oslo, Oslo, Norway
| | - Stine H. Kresse
- The EuroBoNet Network of Excellence on Bone Tumours
- Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - Marieke L. Kuijjer
- The EuroBoNet Network of Excellence on Bone Tumours
- Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Massimo Serra
- The EuroBoNet Network of Excellence on Bone Tumours
- Laboratory of Experimental Oncology, Rizzoli Orthopaedic Institute, Bologna, Italy
| | - Horst Bürger
- The EuroBoNet Network of Excellence on Bone Tumours
- Institute of Pathology, University of Münster, Münster, Germany
| | - Anne-Marie Cleton-Jansen
- The EuroBoNet Network of Excellence on Bone Tumours
- Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Ola Myklebost
- The EuroBoNet Network of Excellence on Bone Tumours
- Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
- Norwegian Microarray Consortium, Department of Molecular Biosciences, University of Oslo, Oslo, Norway
- * E-mail:
| |
Collapse
|